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mellitus (T1DM) patients with age-; height and sex-matched healthy-non-smokers (HNS).
Population and methods: Subjects aged 35–60 Yrs who have a poorly controlled T1DM
(glycated-Haemoglobin level >7%) with a disease history of more than 10 Yrs (n= 14) and
HNS subjects (n= 14) were recruited. Clinical, anthropometric and fasting biological data werecarbon-
-forced-
; HNS,
ry-ﬂow;
tilatory-
cic-gas-
ciety of
ment of
.: +216
rculosis.
718 I. Slim et al.Aging;
Case-control study
collected. Plethysmographic data (ﬂows, volumes, estimated-lung-age (ELA), lung-capacity-to-
transfer-carbon-monoxide (DLCO)) were measured. Large-airway-obstructive-ventilatory-defect
(LAOVD) was deﬁned as ﬁrst–second-forced-expiratory-volume (FEV1)/forced-vital-capacity
(FVC) below the lower-limit-of-normal (LLN). Restrictive-ventilatory-defect (RVD) was deﬁned
as total-lung-capacity (TLC) < LLN. Lung-hyperinﬂation was deﬁned as residual-volume
(RV) > upper-limit-of-normal. Student t-test and chi-2 test were used to compare plethysmo-
graphic data and proﬁles of the two groups.
Results: The two groups were matched in chronological-lung-age (CLA) (respectively 47 ± 7 vs.
50 ± 8 Yrs) and sex (7 males and 7 females in each group) and height. Compared to the HNS
group, the T1DM one had signiﬁcantly lower FEV1, FVC, slow-vital-capacity and maximal-mid-
expiratory-ﬂow (respectively 99 ± 11% vs. 83 ± 11%, 99 ± 9% vs. 86 ± 11%, 80 ± 8% vs.
67 ± 15% and 98 ± 23% vs. 72 ± 23%), had signiﬁcantly higher TLC and RV (respectively,
105 ± 20% vs. 123 ± 24% and 108 ± 22% vs. 131 ± 24%) and had signiﬁcantly higher percent-
age of subjects with lung-hyperinﬂation (7.1% vs. 43.0%). Both groups had similar percentages of
LAOVD and RVD and similar corrected DLCO values. ELA of the T1DM group (57 ± 10 Yrs)
was signiﬁcantly higher than CLA.
Conclusion: Poorly controlled T1DM seems to alter ventilatory mechanics without effect on the
alveolo-capillary-membrane. In addition, it accelerates the respiratory ageing.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Diabetes-mellitus (DM), classiﬁed among the top ten leading
causes of death worldwide [1], is becoming a major public
health emergency [2]. In the Maghreb, a region undergoing
an epidemiological transition characterized by a decrease of
infectious diseases and an increase in chronic non-infectious
ones, the prevalence of DM was as high as 9.5% in 2012 [3].
There are twomajor types of DM: type 1 (T1DM) and type 2
(T2DM)); differentiated according to the aetiopathogenic fac-
tors and the rapidity of pancreatic beta cells of Langerhans islets
apoptosis [4]. Since the discovery of insulin, the outcome of
T1DM has completely changed. Treatment options and extra-
renal-epuration techniques are considered as a turning point
in the disease history leading to the improvement of its outcome
[5]. Since then, we are no longer worried about the direct mor-
tality of the disease as much about morbidity associated to
metabolic emergencies, and to micro- and macroangiopathy
[6] which, in turn, may have a negative impact on the function
of internal organs [7]. In fact, diabetic microangiopathy speciﬁ-
cally affects the eyes (retinopathy), kidney (nephropathy) and
peripheral nervous system (neuropathy) [7]. Since it possesses
a very wide capillary network and a signiﬁcant amount of con-
nective tissue, the lung could be a suitable ‘‘target organ’’ [8].
This was earlier suggested by Schuyler et al. [9] more than
40 Yrs ago. These authors [9] investigated lung function in 11
patients with T1DM and age-matched normal control subjects.
This pilot study was the ﬁrst to report measurements of nearly
all the available tests of lung function, including lung elasticity,
capacity-to-transfer-carbon-monoxide (DLCO), absolute tho-
racic-gas-volumes (TGV), airﬂow resistance and maximal
forced-vital-capacity (FVC) tests [9]. As their subjects were life-
long non-smokers without allergies or lung disease, the T1DM
lung elastic recoil decrease was interpreted to reﬂect effects of
DM on lung elastic proteins [9]. That was hence the ﬁrst results
in the literature suggesting that the lung may be a ‘‘target
organ’’ of T1DM. Since then, studies analysing T1DM
ventilatory mechanics and/or pulmonary exchanger are morenumerous with controversial conclusions: no effect [9–13],
abnormal data [14–27] with conﬂicting reports on the nature
of spirometric alterations: restrictive [14–17] and/or large-air-
ways obstructive [16,17]-ventilatory-defects (respectively,
RVD, and LAOVD) and/or decreased DLCO [14,15,18,
23,26], and normal spirometry data but decreased DLCO [27].
In addition, the majority of these studies [9–27] used limited
methodology: combination of the two types of DM [14,19–
22]; inclusion of T1DMpatients with a high difference in disease
duration [17]; inclusion of both controlled and uncontrolled
T1DM [21]; lack of control groups such as healthy-subjects
[17,19]; measurements of expiratory ﬂows only [14,17,20,
21,24], without measurement of lung volumes and/or lung-hy-
perinﬂation; non-application [10,17,21,22,24] of the latest lung
function international recommendations [28–30], no report of
the applied lung function guidelines [14,19,20,23]; use of
unspeciﬁed spirometric norms [10,14,17,19,22–24] or of inap-
propriate spirometric deﬁnitions [14,17,19,23] (e.g. application
of a ﬁxed thresholds of 70% or 80% as a lower-limit-of-normal
(LLN)) and no calculation, in case-control studies [10,14,20,22–
24], of the required sample size which is a statistically crucial
point [31]. A recent metaanalysis [32] concluded that when stud-
ied in the absence of overt pulmonary comorbidity, both T1DM
and T2DM were associated with a modestly impaired pul-
monary function in a restrictive pattern. The results were
irrespective of body-mass-index (BMI), smoking, DM dura-
tion, and glycated-haemoglobin (HbA1c) levels. In subanalyses,
the association seemed to be more pronounced in T2DM than
in T1DM [32].
Taking into account those conﬂicting conclusions about the
effect of T1DM on lung function and the remaining unan-
swered question about the reality of diabetic pulmonary alter-
ation that was recently risen [7], the present study aimed to
compare the lung function parameters (i.e. plethysmographic
and DLCO data measured according to recent lung
function test guidelines [28–30]), of a poorly controlled
T1DM group (HbA1c >7%) having a history of disease more
than 10 Yrs with those of age-, sex- and height matched
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will be no difference between lung function data mean values
in both groups.
Population and methods
Study design
It is a case-control study performed over a period of six-
months with collaboration between Departments of
Physiology and Functional Exploration, of Endocrinology
and Diabetes, Laboratories of Hematology and of
Biochemistry (University Hospital of Farhat HACHED) and
of Biochemistry (Basic Health Group of Sousse), Sousse,
Tunisia. The study approval was obtained from the
Hospital’s Ethics Committee. Written and informed consent
was asked from all study participants. All participants have
received a report of their explorations.
Sample size
The null hypothesis was H0:m1 = m2 and the alternative
hypothesis was Ha:m1 = m2 + d where d is the difference
between two means and n1 and n2 are the sample size for
two groups (T1DM and HNS) such that N= n1 + n2. The
total sample size was estimated using the following formula
[31]: N= ((r+ 1)(Za/2 + Z1b)
2r2)/rd2 where Za is the nor-
mal deviate at a level of signiﬁcance (=2.58 for 1% level of sig-
niﬁcance); Z1b is the normal deviate at 1  b% power with
b% of type II error (=1.28 at 90% statistical power); r equal
to n1/n2, is the ratio of sample size required for two groups
(r = 1 gives the sample size distribution as 1:1 for the two
groups). r and d are the pooled standard-deviation (SD) and
difference of ﬁrst–second-forced-expiratory-volume (FEV1)
means of the two groups. These two values were obtained from
a previous study of similar hypothesis [23] where researcher
found the mean FEV1 (%) in the two groups were 95.19%
and 81.28% respectively and a common SD of 13.48%. The
total sample size for the study was 28 subjects (14 T1DM
and 14 HNS).
Study population
Patients’ group
Only poorly controlled T1DM patients aged 35–60 Yrs with a
history of T1DM of more than 10 Yrs were included. Non-in-
clusion criteria were: controlled T1DM (HbA1c 67%); T2DM,
recent infection or acute metabolic complication (occurred less
than one week before the lung function measurements), history
of asthma, allergic rhinitis, atopy or chronic obstructive pul-
monary disease and oral corticosteroid treatment within four
weeks prior to lung function test or bronchodilators use,
patient under dialysis. Researchers have veriﬁed the folders
and ﬁles of all patients with T1DM followed in the
Department of Endocrinology and Diabetes; and have con-
tacted them.
Control group
HNS aged 35–60 Yrs were recruited among Hospital workers
and the parents of medical school students. Informationalletters clarifying the aims of the study were put up at the
Hospital and the local Medical School. In addition, an article
announcing the need for recruitment of healthy subjects was
posted in a social network service (Facebook pages of the per-
sons implicated in the study). Non-inclusion criteria were: his-
tory of smoking, DM, conﬁrmed cardiovascular or
pulmonary diseases, respiratory symptoms (e.g. chronic cough,
wheezing, dyspnoeaPstage two [33]), thoracic surgery, mental
disease and chronic medication use. The discovery of a
LAOVD and/or a RVD was an exclusion criterion.Medical questionnaire
A medical questionnaire [34] was used to assess several sub-
jects’ characteristics (smoking, medical, surgical and gynae-
cologist-obstetrics histories, medication use, several T1DM
characteristics and dyspnoea [33]). Cigarette and narghile use
was evaluated, respectively, in pack-Yrs (PY) and narghile-
Yrs (NY) [35]. Two groups of patients who have successfully
weaned off smoking (ex-smokers) were deﬁned [0. No, 1.
Yes]. T1DM duration (Yr) and speciﬁc complications
(retinopathy (no/yes), dialysis (no/yes)) were noted. Histories
of cardiovascular diseases were searched: angina, heart rhythm
disorder and arterial hypertension.Physical examination
Sex and age (Yr) were noted. Height (±0.01 m) was measured
with a height gauge shoes removed, heels joined, and back
straight. Weight (±1 kg) was measured and the BMI (kg/m2)
was calculated. Waist circumference (m) was measured [36].
Neurological exam and ‘‘douleur neuropathique 4 questions’’
(DN4) score [37] were conducted in order to assess diabetic
neuropathy. Two groups were identiﬁed [0. No symptomatic
neuropathy (DN4 score <4); 1. Symptomatic neuropathy
(DN4 score P4)].
T1DM diagnosis, metabolic data and applied metabolic
deﬁnitions
The positivity of anti-pancreatic antibodies (antiGAD and/or
antiIA2) at the diagnosis of DM was the proof of the auto-im-
mune aetiology [38]. The following haematological data were
measured/calculated: numbers of blood cells (white (103/mm3),
red (106/mm3) and platelets (103/mm3)) and haemoglobin level
(g/dl). Anaemia was deﬁned as haemoglobin level <12 g/dl in
female and <13 g/dl in male [39]. Two groups were deﬁned [0.
No anaemia; 1. Anaemia]. Leukocytosis [40] was deﬁned as
white-blood-cell count>11.103/mm3. Two groups were deﬁned
[0. No leukocytosis; 1. Leukocytosis]. Fasting-glycaemia
(mmol/l), total-cholesterol (mmol/l) and high-density-lipopro-
tein-cholesterol (HDL-cholesterol, mmol/l) were quantiﬁed by
spectrophotometry. Triglycerides (mmol/l) were quantiﬁed by
the enzymatic-colorimetric method. Low-density-lipoprotein-c-
holesterol (LDL-cholesterol, mmol/l) was calculated [41].
HbA1c (%) was quantiﬁed on haemolysed total blood (turbidi-
metric inhibition immunoassay). Poorly controlled T1DM was
retained when HbA1c >7%. Diabetic nephropathy was
assessed by searching for increased urinary albumin (mg/24 h)
excretion using 24-h collections and serum creatinine (lmol/L)
720 I. Slim et al.[42]. Two groups were deﬁned [0. No diabetic nephropathy
(albuminuria <30 mg/24 h); 1. Diabetic nephropathy
(albuminuriaP30 mg/24 h)].
Lung function measurements
Plethysmographic measurements were performed with a body
plethysmograph (ZAN 500 Body II, Mebgrera¨te GmbH,
Germany), carefully following international recommendations
[29,30]. The plethysmographic technique and the FVC
manoeuvre are extensively described in the Supplementary
data section. The following plethysmographic parameters were
measured/calculated and compared to local predicted values
[43]: FEV1 (L), FVC (L), maximal-mid-expiratory-ﬂow
(MMEF, L/s), slow-vital-capacity (SVC, L), FEV1/FVC and
FEV1/SVC ratios (absolute values), TGV (L), residual-volume
(RV, L) and total-lung-capacity (TLC, L). The following def-
initions were applied: LAOVD: FEV1/SVC and/or FEV1/FVC
ratios <LLN [44]; RVD: TLC <LLN [44] and lung-hy-
perinﬂation: RV >upper-limit-of-normal [45]. DLCO was
measured by the single-breath method performed following
international recommendations [28]. Two DLCO measure-
ments in sitting position were performed on each subject.
Subjects were asked to assume the appropriate position ﬁve
minutes before the test with an interval of at least 15 min
between each DLCO measurement (the best value as a percent-
age of predicted values). The following parameters were mea-
sured/calculated and compared with European predicted
values [46]: DLCO (mmol/min/kPa; %), corrected DLCO
(DLCO predicted for haemoglobin [28] (mmol/min/kPa)). A
DLCO lower than the LLN was considered as abnormal
[28]. In order to evaluate respiratory aging, estimated-lung-
age (ELA, Yrs) was calculated [47].Study conduct
First visit (day one, between 14 hrs. and 16 hrs.): presentation
of the subject to the Department of Endocrinology and
Diabetes; signature of consent; medical and DN4 question-
naires and anthropometric data. Second visit (day two,
between 9 a.m. and 11 a.m.): fasting blood and urine samples,
injection of usual dose of basal and/or prandial insulin (the
thighs site of injection was avoided); normal and standard
breakfast intake (including 200 cc of milk or equivalent in
carbohydrate intake and two 40-carbohydrates portions of
bread or equivalent); lung function measurements.Data analysis
The Kolmogorov–Smirnov test was used to analyse variable
distribution. When the distribution was normal and the vari-
ances were equal, the results were expressed by their
means ± SD and 95% conﬁdence interval (95%CI).
Otherwise, results were expressed by their medians (1st–3rd
quartiles). For plethysmographic data, a percentage of change
was calculated (=(T1DM value  HNS value)/T1DM value)
[24]. T-test and chi-2 test were used to compare, respectively,
quantitative data and percentages. T-test was used to compare
quantitative data of T1DM non-smokers vs. T1DM smokers,of male T1DM vs. male HNS and of female T1DM vs. female
HNS. The associations between plethysmographic data
expressed in percentage predict and HbA1c or T1DM duration
were evaluated by Pearson’s product–moment correlation.
Wilcoxon-test was used to compare the ELA with the chrono-
logical-lung-age (CLA) of the each group. Analyses were car-
ried out using the Statistica statistical software (Statistica
Kernel version 6; Stat Software. France). Signiﬁcance was set
at the 0.05 level.
Results
Descriptive data
Among the 62 examined subjects, only 28 (14 HNS and 14
poorly controlled T1DM) were retained for analysis.
The two group characteristics’ are presented in Tables 1
and 2. The main conclusions of these Tables are: (i) both
groups were age, sex and height matched; (ii) compared to
the HNS group, the poorly controlled T1DM one had signiﬁ-
cantly lower weight, BMI and waist circumference. It also has
signiﬁcantly higher percentages of subjects having history of
cardiovascular diseases or dyslipidemia or who were cigarette
smokers. (iii) Compared to the HNS group, the poorly con-
trolled T1DM one had a signiﬁcantly higher fasting-glycaemia
level, a lower haemoglobin level, a higher percentage of anae-
mic subjects and a lower percentage of subjects with measured
dyslipidemia.
The DM duration mean ± SD (minimum–maximum) was
21 ± 8 (10–32) Yrs. Four patients have a cardiovascular dis-
ease (arterial hypertension (n= 2), angina with arterial hyper-
tension (n= 1) and heart rhythm disorder (n= 1)). Smoking
has been stopped since a mean ± SD duration of 9 ± 8 Yrs
in the ex-smokers group. The mean ± SD of cigarettes use
of the ﬁve male smokers included in the study was 30 ± 15
PY. Only one male patient was ex-narghile smoker (20 NY).
Analytical data
Lung function data and proﬁles of the two groups are pre-
sented in Table 3. Compared to the HNS group, the poorly
controlled T1DM one had signiﬁcantly lower SVC, FVC,
FEV1, MMEF, DLCO (percentage changes were, respectively,
+16%, +13%, +16%, +27% and +16%) and had signiﬁ-
cantly higher TLC, RV (percentage changes were, respectively,
17% and 21%). However, there was no statistically signiﬁ-
cant difference between both groups in corrected DLCO.
Compared to the HNS group, the poorly controlled T1DM
one had signiﬁcantly higher percentages of subjects with
abnormal SVC, FEV1, MMEF and RV.
Table 4 shows the characteristics of the poorly controlled
T1DM group divided by smoking status. There was no signiﬁ-
cant difference between metabolic data of the two groups and
compared with the T1DM non-smokers subgroup, the T1DM
ex-smokers group has signiﬁcantly lower FVC (92 ± 8% vs.
79 ± 10%, respectively) and FEV1 (88 ± 8% vs. 75 ± 11%,
respectively).
Table 5 shows the comparison between T1DM and HNS
groups divided by sex. Compared to HNS females, those with
T1DM had signiﬁcant decreases in FEV1 and FVC. Compared
Table 1 Characteristics of type 1 diabetes-mellitus (T1DM)
and healthy-non-smoker (HNS) groups.
HNS
(n= 14)
T1DM
(n= 14)
Percentage
change
Anthropometric data
Male/female 7/7 7/7
Age (Yr) 49.84 ± 7.99 47.43 ± 7.19 +5
Height (m) 1.63 ± 0.10 1.66 ± 0.10 2
Weight (kg) 80 ± 12 68 ± 12 +15*
Body-mass-index
(kg/m2)
30.4 ± 4.0 25.0 ± 5.0 +18*
Waist circumference (m) 0.97 ± 0.09 0.88 ± 0.12 +9*
Clinical data
DN4 Not
reported
4 ± 3
Symptomatic
neuropathy
Yes 0 (0.0%) 8 (57.2%)*
No 14 (100.0%) 6 (42.8%)*
Diabetic
retinopathy
Yes 0 (0.0%) 8 (57.2%)*
No 14 (100.0%) 6 (42.8%)*
Cigarette use Yes 0 (0.0%) 5 (35.7%)*
No 14 (100.0%) 9 (64.2%)*
Narghile use Yes 0 (0.0%) 1 (7.1%)
No 14 (100.0%) 13 (92.9%)
DyspnoeaP stage
2
Yes 0 (0.0%) 1 (7.1%)
No 14 (100.0%) 13 (92.9%)
History of
Cardiovascular
diseases
Yes 0 (0.0%) 4 (28.5%)*
No 14 (100.0%) 10 (71.5%)*
Dyslipidemia Yes 0 (0.0%) 3 (21.5%)*
No 14 (100.0%) 11 (78.5%)*
Dysthyroidy Yes 0 (0.0%) 2 (14.3%)
No 14 (100.0%) 12 (85.7%)
Abdominal surgery Yes 2 (14.3%) 6 (42.8%)
No 12 (85.7%) 8 (57.2%)
DN4: neurological exam and douleur neuropathique 4 questions.
Percentage change = (T1DM value  HNS value)/HNS value.
Data are mean ± SD for anthropometric data and DN4 and
number (%) for others.
* p<.05 (test-t, or chi-2): HNS vs. T1DM.
Table 2 Biological parameters of type 1 diabetes-mellitus
(T1DM) and healthy-non-smoker (HNS) groups.
HNS
(n= 14)
T1DM
(n= 14)
Percentage
change
Biological data
Fasting-glycaemia
(mmol/L)
5.39 ± 0.54 10.28 ± 5.60 91*
HbA1c (%) Not reported 10.71 ± 1.45
Total-cholesterol
(mmol/L)
4.70 ± 0.55 4.47 ± 0.53 +5
Triglycerides
(mmol/L)
1.11 ± 0.36 0.96 ± 0.53 +14
HDL-C (mmol/L) 1.05 ± 0.37 1.29 ± 0.42 23
LDL-C (mmol/L) 3.15 ± 0.50 2.75 ± 0.55 +13
White-blood-cells
(103/mm3)
6.63 ± 1.16 7.16 ± 2.16 8
Red-blood-cells
(106/mm3)
4.59 ± 0.32 4.29 ± 0.47 +7
Platelets (103/mm3) 227 ± 44 249 ± 66 10
Haemoglobin (g/dl) 13.5 ± 1.1 11.6 ± 1.7 +14*
Serum-creatinine
(lmol/L)
81.79 ± 14.27 91.43 ± 37.01 12
Urinary-albumin
(mg/24 h)
NR 8.91 ± 8.17
Biological disorders
Anaemia Yes 2 (14.3%) 12 (85.7%)*
No 12 (85.7%) 2 (14.3%)*
Leukocytosis Yes 0 (0.0%) 1 (7.1%)
No 14 (100.0%) 13 (92.9%)
Diabetic
nephropathy
Yes NR 2 (14.3%)
No NR 12 (85.7%)
NR: not reported. Percentage change = (T1DM value  HNS
value)/HNS value. Data are mean ± SD for biological data and
number (%) for others.
* p<.05 (test-t, or chi-2): HNS vs. T1DM.
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FEV1, FVC and SVC as well as a signiﬁcant increase in RV.
No signiﬁcant correlation between HbA1c or DM duration
and none of the plethysmographic data was found.
The ELA of the T1DM group was signiﬁcantly higher than
the CLA, respectively, 56.70 ± 9.89 vs. 47.43 ± 7.19 Yrs
(p= 0.012). However, no statistical signiﬁcant difference was
found between the HNS group ELA and CLA, respectively,
52.02 ± 7.18 vs. 47.49 ± 7.99 Yrs (p= 0.454).
Discussion
The present study shows impaired lung function parameters in
14 patients with poorly controlled T1DM compared to age-,
sex- and height matched controls. Therefore, the null hypothe-
sis, that there will be no difference between the two groups’
lung function data mean values’ was rejected. This impairment
was associated neither with the T1DMmean duration nor with
the HbA1c levels. In addition, T1DM seems accelerating the
respiratory ageing.Discussion of the methodology
A Medline/PubMed research was conducted on 8 June 2014
and using the following three Medical Subject Headings
‘‘Diabetes Mellitus, Type 1’’ and ‘‘Respiratory Function
Tests’’ and ‘‘Adults’’. Among bibliographies of retrieved
articles that were manually reviewed, only international
studies published during the last 10 Yrs and all published
African studies were retained. Supplementary Tables 1E
and 2E describe, respectively, the ﬁve international and the
four African published studies [10,14,17,19–24]. The above
studies have controversial conclusions and used limited
methodology:
 Combination of the two types of DM [14,19–23]. This could
be a source of ‘‘confusion’’ because they have different
aetiopathogenies. Unlike T2DM during which the apopto-
sis occurs slowly and mainly due to glucotoxicity and lipo-
toxicity [4], T1DM is associated with a very fast and
irreversible apoptosis provoked by auto-immune factors
that are genetically programmed [48].
 Inclusion of T1DM patients with a high difference in disease
duration [17]. The DM duration varied from three (range:
0.5–13 Yrs) [17] to 15 ± 7 Yrs [10]. This could be a source
Table 3 Lung function data and plethysmographic proﬁles of
type 1 diabetes-mellitus (T1DM) and healthy-non-smoker
(HNS) groups.
HNS
(n= 14)
T1DM
(n= 14)
Percentage
change
Plethysmographic and DLCO data (data are mean ± SD)
SVC (%) 80 ± 8 67 ± 15 +16*
FVC (%) 99 ± 9 86 ± 11 +13*
FEV1 (%) 99 ± 11 83 ± 11 +16
*
FEV1/SVC (absolute
value)
0.8 ± 0.05 0.8 ± 0.10 +0
FEV1/FVC (absolute
value)
0.8 ± 0.03 0.8 ± 0.07 +0
MMEF (%) 98 ± 23 72 ± 23 +27*
TGV (%) 97 ± 7 94 ± 12 +3
TLC (%) 105 ± 20 123 ± 24 17*
RV (%) 108 ± 22 131 ± 24 21*
DLCO (%) 109 ± 21 92 ± 22 +16*
Corrected DLCO
(%)
113 ± 24 113 ± 42 +0
Lung function proﬁles (data are number (%))
HNS (n= 14) T1DM (n= 14) Probability
Plethysmographic data or DLCO lower than the lower-limit-of-
normal
FVC 0 (0.0%) 2 (14.3%)
SVC 4 (28.5%) 12 (85.7%) #
FEV1 0 (0.0%) 3 (21.5%)
#
FEV1/FVC 0 (0.0%) 0 (0.0%)
FEV1/SVC 0 (0.0%) 0 (0.0%)
MMEF 0 (0.0%) 3 (21.5%) #
TLC 0 (0.0%) 1 (7.1%)
DLCO 1 (7.1%) 3 (21.5%)
Corrected DLCO 2 (14.3%) 1 (7.1%)
Plethysmographic data higher than the upper-lower-of-normal
RV 1 (7.1%) 6 (43.0%) #
For abbreviations, see list of abbreviations. %: percent of predicted
values. Percentage change = (HNS value  T1DM value)/HNS
value.
* p< 0.05 (test-t): HNS vs. T1DM.
# p< 0.05 (chi-2): HNS vs. T1DM.
Table 4 Characteristics of type 1 diabetes mellitus group
divided by smoking status.
Non-smokers
(n= 8)
Ex-smokers
(n= 6)
Percentage
change
Anthropometric data
Male/female 1/7 6/0
CLA (Yr) 46.29 ± 7.90 48.96 ± 6.51 6
ELA (Yr) 53.63 ± 7.90 59.56 ± 11.95 11
Height (m) 1.61 ± 0.08 1.72 ± 0.09 7*
Weight (kg) 69 ± 14 68 ± 10 +1
BMI (kg.m2) 26.5 ± 5.72 23.0 ± 3.3 +13
Waist
circumference (m)
91 ± 14 84 ± 7 +8
Metabolic data
Fasting-glycaemia
(mmol/L)
10.68 ± 4.648 9.75 ± 7.13 +9
HbA1c (%) 11.14 ± 1.458 10.13 ± 1.35 +9
Total-cholesterol
(mmol/L)
4.64 ± 0.458 4.24 ± 0.56 +9
Triglycerides
(mmol/L)
1.03 ± 0.385 0.87 ± 0.72 +16
HDL-C (mmol/L) 1.39 ± 0.359 1.15 ± 0.48 +17
LDL-C (mmol/L) 2.78 ± 0.527 2.70 ± 0.63 +3
White-blood-cells
(103/mm3)
7.23 ± 2.78 7.06 ± 1.16 +2
Red-blood-cells
(106/mm3)
4.23 ± 0.41 4.37 ± 0.56 3
Platelets
(103/mm3)
268 ± 64 223 ± 64 +17
Haemoglobin
(g/dl)
11.2 ± 0.9 12.2 ± 2.4 9
Serum creatinin
(lmol/L)
88.13 ± 40.26 95.83 ± 35.38 9
Urinary albumin
(mg/24 h)
8.91 ± 9.97 8.91 ± 5.88 +0
Plethysmographic and DLCO data
FEV1/SVC
(absolute value)
0.86 ± 0.11 0.79 ± 0.07 +8
FEV1/FVC
(absolute value)
0.82 ± 0.07 0.78 ± 0.08 +5
FVC (%) 92 ± 8 79 ± 10 +14*
FEV1 (%) 88 ± 8 75 ± 11 +15
*
MMEF (%) 77 ± 20 64 ± 26 +17
SVC (%) 67 ± 20 67 ± 6 +0
TGV (%) 99 ± 12 87 ± 8 +12
TLC (%) 126 ± 26 119 ± 24 +6
RV (%) 140 ± 26 118 ± 16 +16
DLCO (%) 92 ± 13 93 ± 31 1
Corrected DLCO
(%)
96 ± 19 136 ± 54 42
For abbreviations, see list of abbreviations. %: percent of predicted
values. Percentage change = (ex-smokers value  non-smokers
value)/ex-smokers value. Data are mean ± SD for biological data
and number (%) for others.
* p<.05 (test-t) non-smokers vs. ex-smokers.
 p<.05 (Wilcoxon matched pairs test) for the same group.
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the duration of T1DM is, the greater the lung function
impairment will be [24]. T1DM mean duration of the pre-
sent study (21 ± 8 Yrs) was higher than what was reported
in other studies (Tables 1E and 2E).
 Inclusion of both controlled and uncontrolled T1DM (respec-
tively, 40% and 60% in Hickson et al. [21] study). This
could be a source of confusion since it was demonstrated
that the uncontrolled DM group, when compared to con-
trolled one, has a signiﬁcant decrease in lung function
[20]. Unlike the majority of the published studies [9–27],
the present study included only poorly controlled patients.
 Lack of the control group such as healthy-subjects [17,19].
Cross-sectional studies [14,24], while practical, do not pro-
vide a good basis for establishing causality.
 Measurements of expiratory ﬂows only [14,17,20,21,24],
without measurement of lung volumes (useful parameters
for the diagnosis of RVD [44] and/or lung-hyperinﬂation[45]) or DLCO [10,19,23] (useful for the evaluation of the
alveolar-capillary-membrane [28]) or lung-age. One positive
point for the present study, as done by others [10,19], was
the correction of DLCO according to haemoglobin levels
[28]. Lung age, a parameter not previously evaluated, has
Table 5 Comparison between the type 1 diabetes mellitus (T1DM) and healthy non-smoker (HNS) groups divided by sex.
Females Males
T1DM (n= 7) HNS (n= 7) T1DM (n= 7) HNS (n= 7)
Anthropometric data
CLA (Yr) 46.77 ± 8.40 49.37 ± 7.94 48.09 ± 6.37 50.30 ± 8.64
Height (m) 1.60 ± 0.08 1.54 ± 0.07 1.72 ± 0.08 1.71 ± 0.04
Weight (kg) 71 ± 14 76 ± 12 66 ± 10 84 ± 12*
BMI (kg.m2) 27.6 ± 5.16 31.9 ± 2.83 22.4 ± 3.4 28.8 ± 4.5*
Waist circumference (m) 93.86 ± 12.60 94.7 ± 4.31 82.29 ± 8.26 99.43 ± 11.30*
Metabolic data
Fasting-glycaemia (mmol/L) 11.34 ± 4.59 5.40 ± 0.60* 9.21 ± 6.66 5.39 ± 0.52*
Total-cholesterol (mmol/L) 4.66 ± 0.49 4.86 ± 0.69 4.27 ± 0.52 4.54 ± 0.34
Triglycerides (mmol/L) 0.96 ± 0.36 1.13 ± 0.36 0.96 ± 0.70 1.09 ± 0.40
HDL-C (mmol/L) 1.42 ± 0.38 1.17 ± 0.38 1.15 ± 0.44 0.93 ± 0.35
LDL-C (mmol/L) 2.81 ± 0.57 3.18 ± 0.64 2.69 ± 0.57 3.13 ± 0.35
White-blood-cells (103/mm3) 7.30 ± 2.99 6.67 ± 1.35 7.02 ± 1.07 6.58 ± 1.03
Red-blood-cells (106/mm3) 4.16 ± 0.39 4.41 ± 0.32 4.42 ± 0.53 4.76 ± 0.21
Platelets (103/mm3) 267 ± 70 227 ± 46 231 ± 62 228 ± 47
Haemoglobin (g/dl) 11.0 ± 0.8 12.8 ± 1.0* 12 ± 2 14 ± 1*
Serum-creatinin (lmol/L) 90.86 ± 42.68 71.14 ± 6.52 92.00 ± 33.85 92.43 ± 11.59
Plethysmographic data
FEV1 (%) 87 ± 7 101 ± 9
* 79 ± 13 98 ± 12*
FVC (%) 93 ± 8 103 ± 9* 80 ± 10 95 ± 9*
MMEF (%) 75 ± 21 96 ± 21 68 ± 26 99 ± 28
FEV1/SVC (absolute value) 0.85 ± 0.11 0.86 ± 0.05 0.81 ± 0.08 0.83 ± 0.04
FEV1/FVC (absolute value) 0.80 ± 0.05 0.83 ± 0.02 0.80 ± 0.10 0.83 ± 0.04
SVC (%) 66 ± 21 79 ± 8 68 ± 6 81 ± 9*
TGV (%) 121 ± 24 108 ± 26 125 ± 27 103 ± 13
RV (%) 139 ± 28 114 ± 25 122 ± 18 101 ± 18*
TLC (%) 99 ± 12 102 ± 7 89 ± 9 93 ± 3
DLCO (%) 91 ± 14 108 ± 28 94 ± 29 111 ± 13
Corrected DLCO (%) 91 ± 14 108 ± 28 135 ± 49 118 ± 20
For abbreviations, see list of abbreviations. %: percent of predicted values. Data are mean ± SD.
* p<.05 (t-test): T1DM vs. HNS for each sex.
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metric results for smokers and/or patients with respiratory
impairment [47].
 Non-application in some studies [10,17,21,22,24] of the latest
lung function international recommendations [28–30]. While
old recommendations (American-thoracic-society (ATS)-
1987 [49] or ATS-1995 [50]) were applied in some studies
[10,17,21,22,24], the present one predated recent guidelines
[28–30]. Surprisingly, the published African studies
[14,19,20,23] have not mentioned which spirometry guide-
lines were used.
 Use of unspeciﬁed spirometric norms [10,14,17,19,22–24].
This could lead to misinterpretation of spirometry data in
a signiﬁcant proportion of subjects [43] since spirometry
results are often expressed as percentage of predicted values
derived from local reference equations [43].
 Use of inappropriate spirometric deﬁnitions (e.g. application
of a ﬁxed thresholds of 70% or 80% as a LLN [10,14,17,19–
24]). This approach has been widely criticized and more
importantly, clinicians may have to review and revise pre-
vious diagnosis [51]. The present study applied the recent
international deﬁnitions based on a 95%CI [44].
Paradoxically, in some studies [10,20–22,24], the applied
spirometric deﬁnitions to diagnosis ventilatory-defects were
not reported. Use of old spirometry equipment [21]. Hickson et al. [21]
results were calculated using an equipment (dry rolling-seal
spirometers) that gave different results than those currently
recommended by the ATS/ERS [29]. However, lung
function testing equipment and procedures have been
progressively reﬁned over the last 10 Yrs in line with
recommendations that have been regularly updated by the
ATS/ERS [28–30].
 No calculation, in some case-control studies [10,14,20,22–24],
of the required sample size. This could be a statistically cru-
cial point [31]. The present study calculated sample size of
T1DM (n= 14) which was higher than the sample size of
some studies (n= 8 [19]; n= 12 [10]), but was smaller than
the sample size of other ones (n= 20 [52]; n= 27 [23,24];
n= 30 [14]; n= 39 [17]).Populations’ characteristics
The percentage of T1DM patients with symptomatic diabetic
neuropathy (57.2%, Table 1) was similar to that reported in
the literature (65.3% [53]). The mean age of the patients group
in the present study (47 ± 7 Yrs) was intermediate with those
reported in other studies: it varied from 14 ± 6 (range: 7–
28 Yrs) [17] to 54 ± 10 Yrs [22]. It has been proved that
724 I. Slim et al.T1DM [54] and lung function [55] are sex-dependent. For that
reason, and as done in some studies [17,19,21–23], the present
one was sex-matched.
Limits of the present study
One major limitation of the present study was the inclusion of
six males T1DM ex-smokers (43%). This inclusion makes the
T1DM sample’s proﬁle questionable and the question that
may be raised here is: ‘‘should current- or ex-smokers be
included in the T1DM patient group?’’ In similar studies
(Table 3E) performed among T1DM [26,52], or T2DM [56–
58] or mixed-patients [59,60], 5% [26], 10% [58], 19% [56],
24% [59], 30% [52], 37% [57] and 50% [60] of DM patients
were current-smokers and 12.5% [58], 18.4% [59] and 33%
[56,60] were ex-smokers. In addition, and due to the high
prevalence of smoking in DM patients (22% to 33% of them
are smokers [61,62]), the inclusion of subjects with such risk
factors make the samples more representative especially of
poorly controlled patients. Moreover, comparisons between
female or male groups (T1DM vs. HNS) showed the same lung
function impairment (Tables 4 and 5). So, restricting the analy-
sis to T1DM females who had never smoked, did not alter the
present study ﬁndings. At least a recent study [63] have exam-
ined pulmonary function in smokers with a >10-PY with and
without diabetes. Authors have concluded that participants
with DM were observed to have reduced pulmonary function
after controlling for known risk factors such as smoking [63].
Finally, in a systematic review and meta-analysis investigating
pulmonary function in DM, metaregression analyses showed
that between-study heterogeneity was not explained by BMI,
smoking, diabetes duration, or HbA1c [32].
Additional discussion about the study design, recruitment
method, medical questionnaire and data analysis is detailed
in the Supplementary data section.
Discussion of the results
Effect of T1DM on lung ﬂows and ratios
Results about the T1DM effect on peripheral ﬂows (e.g.
MMEF) are controversial: unchanged [10,19,24] vs. decreased
[14,20,23] values. In the present study, the reduction of MMEF
by 27% (Table 3) can be considered as a marker of small air-
way defect. It is fair to assume that the small airways are a
potential target for T1DM and other speciﬁed studies are wel-
come. In a case-control study [10] (12 T1DM non-athletes vs.
12 healthy-non-athletes), no statistical differences between
FEV1 and FVC values were found (Table 1E). In another
study [19], the FEV1 of the 23 DM patients was qualiﬁed as
normal (>80%) (Table 2E). However, in line with the major-
ity of studies [14,20–24], the present one conﬁrms that T1DM
reduces FEV1 and FVC. These results are a marker of a large
airway defect[64]: the FEV1 and/or FVC reduction by almost
0.300 L (13–16%) is higher than the spontaneous variability
observed in healthy subjects (of 0.183 L for FEV1 and
0.148 L for FVC [44]) and higher than the 0.200 L (12%)
threshold used in reversibility test interpretation [44]. Is
T1DM incriminated in the genesis of LAOVD? Data aiming
to respond to that question are still controversial: whereas
some studies [14,20,23] show a decrease in FEV1/FVC ratio,the present study (Table 3), like others [10,24] (Tables 1E
and 2E), does not support this hypothesis and shows
unchanged FEV1/FVC ratio between T1DM and HNS groups.
In addition, FEV1/SVC was not affected by T1DM, as pre-
viously shown by Berriche et al. [19].
Effect of T1DM on lung volumes
Data about the effect of T1DM on lung volumes are contro-
versial (Tables 1E and 2E). As observed in the present study,
SVC was signiﬁcantly decreased in some other case-control
studies [22,23]. It was, however, qualiﬁed as normal (>80%)
with Berriche et al. [19]. In practice, SVC is an important
parameter used to diagnose LAOVD [64] or ‘‘trapping phe-
nomena’’ [29]. Contrary to Masmoudi et al. [23] study, where
TLC was decreased showing a tendency to a RVD, the present
study objectiﬁes an increase in TLC values showing a tendency
to lung-hyperinﬂation. Some other studies [10,19] found no
signiﬁcant change in TLC (Tables 1E and 2E). One major
result of the present study was the signiﬁcant increase of RV
in T1DM (Table 3). RV is an interesting parameter used in
practice to diagnose lung-hyperinﬂation [45] and the 0.400 L
(21%) RV increase is signiﬁcantly higher than the recom-
mended threshold of 0.300 L (10%) applied in reversibility test
interpretation [45]. The present result was in opposition to the
ﬁndings of Berriche et al. [19] where DM patients RV was
lower than 80%.
Effect of T1DM on DLCO
The present study T1DM group DLCO was signiﬁcantly
decreased (Table 3), which probably indicates a parenchyma
dysfunction. However, as DLCO changes with haemoglobin
levels and as the T1DM group has a statistically lower haemo-
globin level (Table 2) and includes a statistically higher per-
centage of anaemic subjects, speciﬁc adjustments for this
parameter (e.g. use of corrected DLCO) should always be
made to ensure appropriate interpretation [28]. In the present
study, as found by others [10], corrected DLCO values were
unchanged (Table 3). On the contrary, a signiﬁcant decrease
in corrected DLCO was noticed in a previous study [23].
However the haemoglobin level was not reported [23]
(Table 2E).
Plethysmographic and DLCO proﬁles
No patient with T1DM had LAOVD (Table 3). This result,
different from the one found by Suresh et al. [17] (7.7% of
T1DM present a LAOVD), is explained by the divergence in
the applied deﬁnitions to retain the LAOVD diagnosis
(FEV1 <80% and FVC >80% or FEV1/FVC < 0.70 in
Suresh et al. study [17] vs. FEV1/FVC or FEV1/SVC< LLN
in the present one). In fact, applied in the present study,
Suresh et al. [17] deﬁnition gives a percentage of 21.4%. Half
of T1DM patients had lung-hyperinﬂation (Table 3). This
result, not previously reported, had a practical interest. It
was shown that lung-hyperinﬂation has important conse-
quences that surpass the framework of respiratory mechanics
[45]. Almost seven percent of T1DM patients had RVD
(Table 3), which is much lower than the 43.6% reported by
Suresh et al. [17]. This difference could be explained by the
divergence in the applied deﬁnitions to retain the RVD diagno-
sis (FVC <80% and FEV1/FVC>0.7 [17] vs. TLC < LLN in
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deﬁnition, in the present study, gives a percentage of 21.5%. In
Abd El-Azeem et al. [14] study, respiratory-defect was pre-
dominantly restrictive (no percentage was given). Applied in
the present study, the deﬁnition used by Abd El-Azeem et al.
[14] (normal FEV1/FVC and reduced DLCO) to diagnose
RVD, gives a percentage of 21.5%. Almost one ﬁfth of
T1DM patients had decreased DLCO values (Table 3). This
percentage becomes 7.1%, when DLCO was adjusted for hae-
moglobin levels (Table 3). To the best of the authors’ knowl-
edge, no previous study has reported a percentage of T1DM
with abnormal DLCO.
Correlation between HbA1c or DM duration and
plethysmographic data
Like some studies [17,19,21] including T1DM patients with a
high HbA1c level, the present one, do not ﬁnd a signiﬁcant
correlation between HbA1c and lung function data. This result
conﬁrms that HbA1c, a classical biological data often used to
monitor the development of T1DM, does not appear as an
indicator of respiratory deﬁciency. Lung function data, too,
does not appear to be inﬂuenced by disease duration
[14,17,19,21], which is conﬁrmed by the present study, carried
out on patients with a mean duration of T1DM of 21 Yrs.
However, Meo et al. [24] have concluded that the years of dis-
ease showed a dose–response effect on lung function: the
longer the duration of disease, the greater the lung function
impairment.
T1DM and respiratory aging
One of the major results of the present study was that T1DM
accelerated lung ageing by 8.74 ± 8.63 Yrs. This phenomenon
seemed to be accelerated by smoking status. In fact, compared
to T1DM non-smokers, those smokers have a signiﬁcant
acceleration of lung ageing (7.35 ± 7.94 vs. 10.61 ± 9.28).
This result, not previously described, could be used to encour-
age smoking cessation [65].
How T1DM alters lung function?
The aetiology of ‘‘diabetic pneumopathy’’ (i.e. a typical
histopathological and functional lung involvement) [25] is still
a matter of debate. The development of this long-term com-
plication could be explained by the biochemical alteration of
connective tissue proteins as well as microangiopathy of pul-
monary vessels [8,66], leading to mechanical lung dysfunction
and impaired blood gas exchange [67]. The mechanisms by
which T1DM could alter lung function are detailed in the
Supplementary data section.
Practical recommendations
It is advisable that patients with T1DM, mainly the poorly
controlled ones with duration of disease longer than 10 Yrs,
should undergo periodic plethysmographic tests (e.g. one
test/year) to assess the severity of lung function impairment
[24]. Plethysmography will identify more susceptible patients
with T1DM; so that they will be able to take additional pre-
ventive measures towards lung damage [24]. These measures
will help to prevent lung damage at the initial stage, which
often, over in the long run, contributes to morbidity and mor-
tality in diabetic patients [24]. Additionally, physicians shouldcontemplate the lung in the same way as any other com-
plications of T1DM. They should also recognize the size of
the problem of pulmonary complications as a consequence
of the novel techniques used through the respiratory tract in
the treatment of DM such as insulin pump inhaler [68].
Finally, in order to motivate T1DM smokers to stop smoking,
it is very useful to convey to them data about their ELA
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